Engine Biosciences

Active#39 in Singapore

Estimated valuation · AI drug discovery · Singapore

Precision-oncology drug developer that combines high-throughput gene-interaction experiments with machine learning to discover and advance targeted cancer therapies.

Biotech›AI drug discovery enginebio.com

Founded2017

HQSingapore

RaisedUSD 86M

Last roundSeries A extension · Oct 2023

Country of originSingaporeListed in the Singapore ranking

Where would you invest?SingaporeJurisdiction as cited by the ranking

Estimated valuation

AI · Singapore ranking

≈ USD 140MUSD 70–280M · Hundreds of M$

Hundreds of k$

Millions $

Tens of M$

Hundreds of M$

Unicorn

Decacorn

Hectocorn

Anchor: Last known equity round: Series A extension · USD 27M · Oct 2023
AI adjustment: None

An indicative editorial estimate produced by AI, imperfect by nature: neither a financial valuation nor investment advice. Only the market sets a company’s value. Method

Uback rankings

How the AI ranks →

Ranking	Tier	Rank	Edition	Next update
Singapore · all sectors	Top 50	#39	Edition 0 · October 2026	2 Nov 2026

Rank historyOct 2026 · #39First edition: no movements yet.

Funding history

USD 86M raised in total

Date	Round	Amount	Type	Investors
Oct 2023	Series A extension	USD 27M	Equity	Polaris Partners

Rounds as cited by Uback’s rankings. Equity, debt and grants are shown separately; only equity rounds count towards the valuation anchor.

Independent analyses

By industry professionals & analysts

Industry professionals and financial analysts can publish their own analysis of Engine Biosciences as a PDF. It must answer at least one of these four questions, and stick to them:

AI valuation: $140MUndervalued or overvalued?

Versus competitorsHow does it compare?

Who should acquire itStrategic buyers, and why

Who should it acquireAcquisition targets, and why

Publish an analysisName, role and LinkedIn shown · public sources only

Analyses are the opinion of their authors, not of Uback. They are checked before publication.

Invest

Back Engine Biosciences whether or not it has agreed: your intention joins the pool on Engine Biosciences, passed to the Fundraising Desk of its country once it reaches critical mass. Backing on Uback (pronounced “you back”) means declaring an Interest (free) or an Intention (coming soon). Backing does not mean that this company is raising funds or that a shareholder is selling shares, and it is not a commitment to invest. Any deal, through a funding round or a sale by an existing shareholder, is handled by a partner desk: the Fundraising Desk of the country for a round, the Secondary Sales Desk assigned to the company for a sale.

Back Engine Biosciences Or back biotech in Singapore

Pool on Engine BiosciencesBelow threshold

BackersBelow threshold

Paid intention · valid for life · movable until you sign with a partner desk. If the company does not follow up, Uback invites its Backers to move their intentions to a competitor or a similar company. Investing in non-listed companies carries a risk of losing all the capital invested.

Do you run Engine Biosciences?

Claim this profile to correct data, add your logo and description, or tell Uback about an upcoming round.

Claim this profile Report an upcoming round → Report an error →

Are you a shareholder?

Considering selling some of your shares? Tell Uback privately. Nothing is published without your consent, and never a price or a volume.

Tell Uback privately

What the AI reads

Read by the AI at the next edition.

Comparable companies in Singapore

Full Singapore ranking →

Hummingbird Bioscience#12Biotech › antibody therapeuticsHundreds of M$Nuevocor#30Biotech › gene therapyHundreds of M$Allozymes#46Biotech › enzyme engineeringTens of M$Speedoc#38Digital health › hospital at homeHundreds of M$

Last updated: Oct 2026Report an error

Uback is a content publisher and an aggregator of non-binding expressions of interest. It provides no investment advice, receives no mandate and takes part in no transaction. Rankings, ranges and brackets are editorial estimates produced by AI, purely indicative.